Antineoplaston treatment for advanced hepatocellular carcinoma.
Antineoplaston A10 injection (antineoplaston A10 I) exhibited cystostatic growth inhibition of human hepatocellular carcinoma (HCC) cells in vitro and showed minimum adverse effects in a phase I clinical trial. Advanced HCC is hard to control because the potent anticancer drugs or embolizations easily induce hepatic failure. We review herein 2 cases of advanced HCC treated with antineoplaston A10 I. Both cases showed interesting responses to antineoplaston A10 I. One showed massive coagulation necrosis of tumors after intra-arterial infusion of antineoplaston A10 I and the other showed resolution of portal vein tumor thrombosis with systemic infusion of antineoplaston A10 I. The usefulness of anti-neoplaston A10 I in terminal staged HCC is discussed.
Kumabe
T
T
Department of Radiology, Kumabe Hospital, Kurume University School of Medicine, Kurumeshi, Fukuokaken 830-0011, Japan.
Tsuda
H
H
Uchida
M
M
Ogoh
Y
Y
Hayabuchi
N
N
Sata
M
M
Nakashima
O
O
Hara
H
H
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D044482:Benzeneacetamides; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010881:Piperidones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D044482:Benzeneacetamides; D010881:Piperidones; C052091:antineoplaston A10